IP Library › Granted Patent US 12,311,010
Granted Patent B2
US 12,311,010 · App. 18/445,165 · Granted May 27, 2025

Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof

Inventors: David Stover (Los Angeles, CA); Dhruba Bharali (Sherman Oaks, CA); Bruce A Hay (Niskayuna, NY); Tahmineh Safaie (Yucca Valley, CA)
Assignee: Nammi Therapeutics, Inc.
A61K38/177A61K45/06A61K47/543A61K47/6911
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,311,010
App. No.
18/445,165
Granted
May 27, 2025
Kind
B2
Abstract

Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Claims (15)

1. A method of treating a subject diagnosed with cancer comprising administering to a subject in need of such treatment an effective amount of a nanocarrier, wherein the nanocarrier comprises a Toll-like receptor (TLR) prodrug having the following structure

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the nanocarrier is further co-formulated with an immunogenic cell death (ICD) inducing chemotherapeutic.

3. The method of claim 2 , wherein the ICD-inducing chemotherapeutic is selected from the group consisting of doxorubicin (DOX), mitoxantrone (MTO), oxaliplatin (OXA), cyclophosphamide (CP), Bortezomib, Carfilzimib, or Paclitaxel.

4. The method of claim 1 , wherein the nanocarrier is further co-formulated with an immune modulating agent.

5. The method of claim 4 , wherein the immune modulating agent is selected from the group consisting of other TLR agonists, immunogenic-cell death inducing chemotherapeutics, indoleamine 2,3-dioxygenase (IDO) antagonists, stimulator of interferon genes protein (STING) agonists, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, and programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors.

6. The method of claim 1 , wherein the nanocarrier is further co-formulated with an i-Natural Killer T cell (iNTK) activator.

7. The method of claim 6 , wherein the iNTK activator is Alpha-galactosylceramide (α-GalCer).

8. The method of claim 1 , wherein the nanocarrier comprises a lipid nanoparticle (LNP).

9. The method of claim 1 , wherein the nanocarrier comprises a solid-lipid nanoparticle (SLNP).

10. The method of claim 1 , wherein the subject is a human.

11. The method of claim 1 , wherein the cancer is melanoma.

12. The method of claim 1 , wherein the cancer is colorectal cancer.

13. The method of claim 1 , wherein the nanocarrier further comprises an immune modulating agent and is provided in a kit.

14. The method of claim 1 , wherein the nanocarrier further comprises an iNTK activator and is provided in a kit.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2023
From: STOVER, DAVID; BHARALI, DHRUBA; HAY, BRUCE A.; SAFAIE, TAHMINEH
To: NAMMI THERAPEUTICS, INC.
Reel/Frame 064242/0595 →
Continuity (5)
Continuation 18445035 · Mar 10, 2023
Continuation 17803703 · Oct 14, 2022
Continuation 17300227 · Apr 16, 2021
Continuation 16974306 · Dec 21, 2020
Related Publication 20230372442A1 · Nov 23, 2023
References Cited (90)
US 7576068B2 · Averett · 2009 [cited by applicant]
US 8034802B2 · Averett · 2011 [cited by applicant]
US 8211863B2 · Averett · 2012 [cited by applicant]
US 8343497B2 · Shi et al. · 2013 [cited by applicant]
US 8343498B2 · Alexis et al. · 2013 [cited by applicant]
US 8367670B2 · Desai et al. · 2013 [cited by applicant]
US 8535683B2 · Kersten et al. · 2013 [cited by applicant]
US 8562998B2 · Shi et al. · 2013 [cited by applicant]
US 8591905B2 · von Andrian et al. · 2013 [cited by applicant]
US 8629142B2 · Desai et al. · 2014 [cited by applicant]
US 8808703B2 · Wu et al. · 2014 [cited by applicant]
US 8809527B2 · Desai et al. · 2014 [cited by applicant]
US 9045470B2 · Wu et al. · 2015 [cited by applicant]
US 9228184B2 · Guiducci et al. · 2016 [cited by applicant]
US 9233141B2 · Chakraborty et al. · 2016 [cited by applicant]
US 9255111B2 · An et al. · 2016 [cited by applicant]
US 9308239B2 · Thiboutot et al. · 2016 [cited by applicant]
US 9452166B2 · Desal et al. · 2016 [cited by applicant]
US 9517993B2 · Yin et al. · 2016 [cited by applicant]
US 9676818B2 · Salunke et al. · 2017 [cited by applicant]
US 9750803B2 · Irvine et al. · 2017 [cited by applicant]
US 10030067B2 · Golde et al. · 2018 [cited by applicant]
US 10172860B2 · Desai et al. · 2019 [cited by applicant]
US 10414789B2 · Debansky, Jr. et al. · 2019 [cited by applicant]
US 10799580B2 · Seder et al. · 2020 [cited by applicant]
US 20030232074A1 · Lipford et al. · 2003 [cited by applicant]
US 20060172966A1 · Lipford et al. · 2006 [cited by applicant]
US 20090214578A1 · Bauer · 2009 [cited by applicant]
US 20090215710A1 · Upadhyay et al. · 2009 [cited by applicant]
US 20090297533A1 · Lichter et al. · 2009 [cited by applicant]
US 20090306177A1 · Uhlmann et al. · 2009 [cited by applicant]
US 20100129439A1 · Alexis et al. · 2010 [cited by applicant]
US 20100130425A1 · Stenzel-Poore et al. · 2010 [cited by applicant]
US 20110077263A1 · Kast et al. · 2011 [cited by applicant]
US 20120148660A1 · Carson et al. · 2012 [cited by applicant]
US 20130156807A1 · Carson et al. · 2013 [cited by applicant]
US 20130202629A1 · Carson et al. · 2013 [cited by applicant]
US 20130230578A1 · Wightman · 2013 [cited by applicant]
US 20130266584A1 · Schuppan et al. · 2013 [cited by applicant]
US 20140135487A1 · Lipford et al. · 2014 [cited by applicant]
US 20140161725A1 · Morse et al. · 2014 [cited by applicant]
US 20140302120A1 · Carson et al. · 2014 [cited by applicant]
US 20150147276A1 · Ingber et al. · 2015 [cited by applicant]
US 20150225432A1 · Cortez et al. · 2015 [cited by applicant]
US 20150251987A1 · Yin et al. · 2015 [cited by applicant]
US 20160175433A1 · Wightman · 2016 [cited by applicant]
US 20160194381A1 · Thiboutot et al. · 2016 [cited by applicant]
US 20160347791A1 · Caligiuri et al. · 2016 [cited by applicant]
US 20170095573A1 · Oh et al. · 2017 [cited by applicant]
US 20170182152A1 · Alving et al. · 2017 [cited by applicant]
US 20170189521A1 · Wightman · 2017 [cited by applicant]
US 20170333553A1 · Wightman · 2017 [cited by applicant]
US 20180085445A1 · Chow et al. · 2018 [cited by applicant]
US 20180200364A1 · Wightman · 2018 [cited by applicant]
US 20180280497A1 · Seder et al. · 2018 [cited by applicant]
US 20180326051A1 · Wightman · 2018 [cited by applicant]
US 20180344641A1 · Brinker et al. · 2018 [cited by applicant]
US 20190119341A1 · Ramsburg et al. · 2019 [cited by applicant]
US 20190275135A1 · Poolman · 2019 [cited by applicant]
US 20200030441A1 · Wightman · 2020 [cited by applicant]
US 20200085850A1 · Sherwood et al. · 2020 [cited by applicant]
US 20200197534A1 · Mei et al. · 2020 [cited by applicant]
US 20200276299A1 · Fox et al. · 2020 [cited by applicant]
US 20200330581A1 · Black · 2020 [cited by applicant]
US 20200375912A1 · Serda et al. · 2020 [cited by applicant]
US 20210017189A1 · Cheng et al. · 2021 [cited by applicant]
US 20210179621A1 · Yin et al. · 2021 [cited by applicant]
EP 2322178A3 · 2011 [cited by applicant]
WO WO2006028962A1 · 2006 [cited by applicant]
WO WO2009030996A1 · 2009 [cited by applicant]
WO WO2009030998A1 · 2009 [cited by applicant]
WO WO2011085981A1 · 2011 [cited by applicant]
WO WO2014201245A1 · 2014 [cited by applicant]
WO WO2015000022A1 · 2015 [cited by applicant]
WO WO2015171951A1 · 2015 [cited by applicant]
WO WO2017070735A1 · 2017 [cited by applicant]
WO WO2018152396A1 · 2018 [cited by applicant]
Engel, et al., The Pharmacokinetics of Toll-like receptor agonsits and the impact on the Immune System, Expert Rev. Clin. Pharmacol, 4(2): 275-289 (Mar. 2011). [cited by applicant]
Cen, et al., TLR1/2 Specific Small-Molecule Agonsist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes, Adv. Sci. 6, pp. 1-12 (2019). [cited by applicant]
Nakamura, et al., Synthesis and evaluation of 8-oxoadenine derivatives as potent toll-like receptor 7 agonsists . . . , Bioorg. & Med. Chem. Letters 23 (2013) pp. 669-672. [cited by applicant]
Kurimoto, et al., Synthesis and Structure-Activity Relationships of 2-Amino-8-hydroxyadenines as orally . . . Bloorg. & Med. Chem. 11 (2003) pp. 5501-5508. [cited by applicant]
Basith, et al., Toll-like Receptor Modulators: A Patent Review (2006-2010), Expert Opin. Ther. Patents (2011) 21(6) pp. 927-944. [cited by applicant]
Rodell, et al., TLR7/8-agonsist-loaded nanoparticles promote the polarization of tumour-associated . . . Nat. Biomed. Eng. 2:578-588 (2018). [cited by applicant]
Offermanns, et al., Lipopeptides are Effective Stimulators of Tyrosine Phosphorylation in Human Myeloid Cells, Biochem J. 282, pp. 551-557 (1992). [cited by applicant]
Nguyen, et al., The Synthetic Bacterial Lipopeptide Pam3CSK4 Modulates Respiratory Syncytial Virus . . . , Plos Pathogens vol. 6, Issue. 8 pp. 1-13 (Aug. 2010). [cited by applicant]
Mura, et al., Lipid Prodrug Nanocarriers in Cancer Therapy, J. Controlled Release, 208 pp. 25-41 (2015). [cited by applicant]
Smirnov, et al., Vaccine Adjuvant Activity of 3M-052: An imidazoquiniline designed for local activity without . . . , Vaccine (2011), doi: 10.1016/j.vaccine.2011.05.061. [cited by applicant]
Macedo, et al., Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists, Frontiers in Immunology, vol. 10, (Oct. 2019). [cited by applicant]
Genito, et al., Liposomes Containing Monophosphoryl Lipid A and QS-21 Serve as an Effective Adjuvant for Soluble, Vaccine 35 (2017) pp. 3865-3874. [cited by applicant]
Kratz, et al., Prodrug Strategies in Anticancer Chemotherapy, ChemMedChem 2008, 3, 20-53. [cited by applicant]